CR20120301A - Procedimiento de identificación de animales vacunados frente a brucella - Google Patents
Procedimiento de identificación de animales vacunados frente a brucellaInfo
- Publication number
- CR20120301A CR20120301A CR20120301A CR20120301A CR20120301A CR 20120301 A CR20120301 A CR 20120301A CR 20120301 A CR20120301 A CR 20120301A CR 20120301 A CR20120301 A CR 20120301A CR 20120301 A CR20120301 A CR 20120301A
- Authority
- CR
- Costa Rica
- Prior art keywords
- vaccinated animals
- identification procedure
- animals against
- against brucella
- mammals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/098—Brucella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/23—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Brucella (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
- G01N2333/43595—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from coelenteratae, e.g. medusae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente invención se refiere al uso de una cepa de Brucella spp. que expresa la proteína Green Flourescent Protein (GFP) en la elaboración de medicamentos para la prevención de la brucelosis en mamíferos, a las vacunas frente a la brucelosis, y al método para la identificación de los mamíferos a los que se les ha administrado dichas vacunas. Preferiblemente, el método de la invención es un inmunoensayo, y aún más preferiblemente es un ensayo inmunoabsorbente ligado a enzimas (ELISA).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200931101A ES2372187B8 (es) | 2009-12-03 | 2009-12-03 | Procedimiento de identificación de animales vacunados frente a brucella. |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20120301A true CR20120301A (es) | 2013-02-27 |
Family
ID=44114638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20120301A CR20120301A (es) | 2009-12-03 | 2012-06-01 | Procedimiento de identificación de animales vacunados frente a brucella |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP2508201A4 (es) |
CN (1) | CN102781468A (es) |
CR (1) | CR20120301A (es) |
ES (1) | ES2372187B8 (es) |
MX (1) | MX2012006303A (es) |
PE (1) | PE20121648A1 (es) |
WO (1) | WO2011067446A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20201285A1 (es) * | 2017-11-24 | 2020-11-24 | Consejo Superior Investigacion | Cepa vacunal de brucella modificada para el tratamiento de brucelosis |
CN110863031A (zh) * | 2019-09-29 | 2020-03-06 | 安徽医科大学第一附属医院 | 一种检测布鲁菌病治疗效果的标志物及其应用 |
CN111796091B (zh) * | 2020-07-20 | 2023-09-08 | 天康生物制药有限公司 | 用于区分动物感染布氏杆菌或布氏杆菌菌影疫苗的试剂盒 |
WO2022271201A2 (en) * | 2021-01-07 | 2022-12-29 | International Advantage, Inc. | Ace2 and tmprss2 gene expression as predictive markers of covid-19 severity |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004054508A2 (en) * | 2002-12-12 | 2004-07-01 | Walter Reed Army Institute Of Research Department Of The Army | Immunogenic compositions including rough phenotype brucella host strains and complementation dna fragments |
CN101240290B (zh) * | 2008-02-29 | 2011-06-15 | 杭州师范大学 | 一种含绿色荧光蛋白基因的植物转基因表达载体及其构建方法和应用 |
US20100226942A1 (en) * | 2008-10-30 | 2010-09-09 | Schurig Gerhardt G | Producing an immune response for reducing the risk of developing brucellosis |
CN101586120B (zh) * | 2009-07-15 | 2011-06-15 | 中国农业科学院哈尔滨兽医研究所 | 狂犬病病毒Flury-LEP疫苗株反向遗传操作系统及LEP绿色荧光蛋白重组病毒载体 |
-
2009
- 2009-12-03 ES ES200931101A patent/ES2372187B8/es not_active Expired - Fee Related
-
2010
- 2010-11-29 PE PE2012000760A patent/PE20121648A1/es not_active Application Discontinuation
- 2010-11-29 MX MX2012006303A patent/MX2012006303A/es not_active Application Discontinuation
- 2010-11-29 EP EP10834263.5A patent/EP2508201A4/en not_active Withdrawn
- 2010-11-29 WO PCT/ES2010/070784 patent/WO2011067446A1/es active Application Filing
- 2010-11-29 CN CN2010800630275A patent/CN102781468A/zh active Pending
-
2012
- 2012-06-01 CR CR20120301A patent/CR20120301A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ES2372187B1 (es) | 2012-11-26 |
EP2508201A1 (en) | 2012-10-10 |
ES2372187B8 (es) | 2013-04-29 |
WO2011067446A1 (es) | 2011-06-09 |
CN102781468A (zh) | 2012-11-14 |
EP2508201A4 (en) | 2013-08-07 |
ES2372187A1 (es) | 2012-01-17 |
PE20121648A1 (es) | 2012-12-24 |
MX2012006303A (es) | 2012-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201291105A1 (ru) | Пероральная вакцина, содержащая антиген и агонист toll-подобного рецептора | |
CY1118492T1 (el) | Φαρμακοτεχνικες μορφες εμβολιου norovirus | |
CL2017001585A1 (es) | Anticuerpos anti-c5 y métodos para su uso | |
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
ES2621874T3 (es) | Anticuerpos para MUC16 y métodos de uso de los mismos | |
AR078423A1 (es) | Vacunas dirigidas a las celulas de langerhans | |
CY1115091T1 (el) | Διειδικες πρωτεϊνες προσδεσης αντιγονων | |
PE20150646A1 (es) | Metodos de tratamiento de una tauopatia | |
CL2012001650A1 (es) | Fragmento fab de anticuerpo que se une específicamente a la glicoproteína vi (gpvi) humana e induce un fenotipo de reducción de gpvi; composición farmacéutica que comprende dichos fragmentos fab de anticuerpo anti-gpvi; polinucleótido que los codifica; método para su preparación; su uso para evitar el reconocimiento de un fragmento fab de anticuerpo por anticuerpos preexistentes; y su uso para evitar la activación plaquetaria mediante el enmascaramiento del c-terminal de dicho fragmento fab. | |
GT201400049A (es) | "anticuerpos a pcsk9 y usos de los mismo" | |
CR20120310A (es) | Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico | |
CR20130621A (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
CY1117563T1 (el) | Αντισωματα κατα her3 και χρησεις αυτων | |
CL2012002125A1 (es) | Metodo para la purificacion de anticuerpos de una mezcla de proteina en un biorreactor; unidad operacional que se utiliza en el metodo antes descrito. | |
GT201300233A (es) | Receptores de celulas t similares a anticuerpos especificos para un peptido wt1 presentado por hla-a2 | |
CY1115639T1 (el) | Διειδικα αγωνιστικα αντισωματα υποδοχεα θανατου | |
CL2013002888A1 (es) | Anticuerpo que se une peptido antigenico que se obtiene a partir de una proteina tau; composicion farmaceutica que comprende; uso para tratar trastorno o enfermedad neurodegenerativa;kit de ensayo, linea celular (div 2457-2011). | |
CR20130132A (es) | Anticuerpos contra metalproteasa-9 de matriz | |
AR083747A1 (es) | Anticuerpos anti-il-23 | |
CO6362024A2 (es) | Anticuerpos humanos de alta afinidad para el receptor il-4 humano | |
NZ595707A (en) | Cancer antigen helper peptide | |
CO6630180A2 (es) | Composiciones y métodos de uso terapéutico para anticuerpos multivalentes de lrp6 ( proteínas relacionada con lipoproteinas de baja densidad | |
CL2012003094A1 (es) | Anticuerpo bivalente aislado o fragmento bivalente del mismo, que actua sobre lrp6 potenciando una señal wnt al agrupar uno o mas receptores lrp6 en presencia de una proteina de union de lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; y su uso para tratar cancer. | |
CR20110544A (es) | Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7 | |
CR20120301A (es) | Procedimiento de identificación de animales vacunados frente a brucella |